The Role of Ezetimibe in the Treatment of Cardiovascular Disease

Current Atherosclerosis Reports
Anandita AgarwalaSalim S Virani

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Despite the success of treatment of CVD with statin therapy, a number of patients remain at high risk for CVD. Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C). A number of clinical studies evaluating the use of ezetimibe therapy have resulted in discordant data regarding its safety and efficacy. In this review, we discuss the findings from these studies as well as potential indications for the use of ezetimibe for LDL-C lowering and cardiovascular event reduction.

References

May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Apr 16, 2003·Kidney International. Supplement·Colin Baigent, Martin Landry
Feb 21, 2004·Science·Scott W AltmannMichael P Graziano
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
Jun 15, 2004·The American Journal of Cardiology·Christie M BallantyneJoanne Palmisano
Jun 10, 2005·The New England Journal of Medicine·S Joanna CowellUNKNOWN Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators
Jul 22, 2006·International Journal of Clinical Practice·N Capps
Feb 6, 2007·European Heart Journal·Michiel L BotsDiederick E Grobbee
Apr 1, 2008·The New England Journal of Medicine·John J P KasteleinUNKNOWN ENHANCE Investigators
Sep 4, 2008·The New England Journal of Medicine·Richard PetoRobert Califf
Sep 4, 2008·The New England Journal of Medicine·Anne B RossebøUNKNOWN SEAS Investigators
Sep 26, 2008·The New England Journal of Medicine·Catherine M Otto
Jun 15, 2010·Journal of Atherosclerosis and Thrombosis·Kazumi Tsubakio-YamamotoShizuya Yamashita
Apr 1, 2009·Journal of Clinical Lipidology·Alawi A Alsheikh-Ali, Richard H Karas
Nov 19, 2013·Journal of the American College of Cardiology·Neil J StoneUNKNOWN American College of Cardiology/American Heart Association Task Force on Practice Guidelines
May 14, 2014·Current Atherosclerosis Reports·Joan Carles Escolà-GilFrancisco Blanco-Vaca
Jul 30, 2014·JAMA Internal Medicine·Joseph S RossHarlan M Krumholz
Dec 19, 2014·Circulation·Dariush MozaffarianUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Feb 20, 2015·European Heart Journal·Erik S StroesUNKNOWN European Atherosclerosis Society Consensus Panel
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Jun 15, 2015·The American Journal of Medicine·Salim S ViraniChristie M Ballantyne

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.